Xeris Pharmaceuticals Annual Revenue, Number of Employees, Growth and Funding

Claim your profile


Chicago, IL USA
Total Funding:$237.6M
Lead Investor(s):Merieux Développement
Claim your profile

City Ranking

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Xeris Pharmaceuticals's estimated annual revenue is currently $2.5M per year.
  • Xeris Pharmaceuticals received $10.0M in venture funding in March 2018.
  • Xeris Pharmaceuticals's estimated revenue per employee is $15,503
  • Xeris Pharmaceuticals's total funding is $237.6M.

Employee Data

  • Xeris Pharmaceuticals has 159 Employees.
  • Xeris Pharmaceuticals grew their employee count by 85% last year.
  • Xeris Pharmaceuticals currently has 13 job openings.

Executive Contacts

John ShannonChief Operating Officer
Allison WeySenior Vice President, Investor Relations & Corporate Communications
Ed DrowerDirector Quality
Mike DavisDirector, Quality Control
Aziz AlamDirector of Global Regulatory Affairs
John T. MathisRegional Medical Affairs Director
Kristin MarvinDeputy General Counsel and Vice President of Legal Affairs
Kendal KorteDirector of HR and Office Services
Kenneth JohnsonSenior Vice President - Clinical Development, Medical Affairs and QA
Phil EstepaDirector of Device Development (Combination Products)

Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company's proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using syringes, auto-injectors, multi-dose pens, and infusion pumps. Xeris platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol and XeriJect offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Solar Power


Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Raland Complian...
GCE Solutions
Regis Technolog...
Precision Dose
Nexus Pharmaceu...
Care One Pharma...
Fluid Air
Firma Clinical ...

Xeris Pharmaceuticals News

09/05/2019 - Xeris: Preparing For The Gvoke PDUFA

After a three-month PDUFA extension, Xeris Pharmaceuticals and XERS investors are preparing for Gvoke's new PDUFA date on September ...

09/04/2019 - Have Insiders Been Buying Xeris Pharmaceuticals, Inc ...

So shareholders might well want to know whether insiders have been buying or selling shares in Xeris Pharmaceuticals, Inc. (NASDAQ:XERS).

09/06/2019 - Xeris Pharma's Gvoke: Strong Approval Chances, But This Is ...

Xeris Pharma's Gvoke is a stable and ready to use glucagon self-injector therapy. It has shown non-inferiority to Lilly and Novo Nordisk ...

Xeris Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2011-12-13$1.5MACentral Texas Angel NetworkArticle
2016-01-08$41.0MCRedmile GroupArticle
2017-05-19$30.0MCRedmile GroupArticle
2018-03-09$45.0MUndisclosedSilicon Valley BankArticle
2018-03-09$10.0MCMerieux DéveloppementArticle

Xeris Pharmaceuticals Executive Hires

2015-01-09Phillip JohnsonCFOArticle